Could a blood pressure drug slow a leaky heart valve?
NCT ID NCT07539298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether valsartan, a common blood pressure drug, can slow the worsening of atrial functional mitral regurgitation (a leaky heart valve) in 50 adults with normal heart pumping function. Participants take either valsartan or a placebo twice daily for 12 months, with regular heart imaging and safety checks. The goal is to see if the drug reduces valve damage and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Valsartan (a blood pressure medication)
- What this could lead to
- If it works, this could point toward a way to slow the progression of atrial mitral regurgitation without surgery.
- What could go wrong
- This is a small pilot study with only 50 participants, so results may not apply to everyone. Valsartan may not slow the condition and could cause side effects like low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FUNCTIONAL MITRAL REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.